Video

Eleven-Year-Old MPN Hero Remains Positive in the Face of Uncertainty

Author(s):

Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.

Cannon McMullin was diagnosed with essential thrombocythemia (ET) at 8 years old, and now at age 11, has been living with the disease for 3 years. Cannon is the youngest of his siblings but has shown the poise of someone much older than him as he regularly travels for treatments and checkups with his parents, making him an MPN Hero and example for all patients to look too.

While Cannon has had his struggles with the disease the current treatment, he is on has allowed him to live a mostly normal life and continue to pursue the activities he loves, like basketball. Cannon is also a part of a clinical study investigating a new treatment, and Cannon knows that his participation in this trial is vital to the ongoing study of patients with ET, but more importantly, he’s doing it to help patients like him.

In an interview with CURE, Cannon discussed how he remains positive and some of the things he thinks about while undergoing treatment and traveling for meetings with physicians.

TRANSCRIPTION

I just try to think of things that make me happy and just try not to think of the disease that I have. Like, I like sports games or like Call of Duty and fortnight, games like those.

In the summer we live really close to a lake, and so we'll put our kayaks down a little bit down the road then we'll kayak down to the beach and then drive back to our house.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content